Current Report · Items 1.01, 3.02, 5.03, 8.01, 9.01 · 8-K
MARPAI INC
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Other Events
Item 1.01 Entry into a Material Definitive Agreement. On July 29, 2026, Marpai, Inc. (the “Company”) entered into securities purchase agreements (each, a “Securities Purchase Agreement”) with accredited investors relating to an offering (the “Offering”) and the sale of an aggregate of 12,100 shares of newly designated Series A Preferred Stock (the “Preferred Stock”) at a purchase price of $1,000 f…
Filed Jul 31, 2026Accepted Jul 31, 2026, 5:29 PM EDTCIK 1844392Accession 0001213900-26-084129
Company context
Marpai, Inc. (OTCQX: MRAI) is a healthcare technology company providing Third-Party Administration and Pharmacy Benefit Management services. The Company supports self-funded employer health plans with solutions designed to improve plan performance, manage healthcare costs, and enhance member outcomes.
Current securities
Historical securities (2)
Registered securities in this filing
MARPAI, INC. · 8-K · Filed 2026-07-31
As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.
Class A Common Stock, par value $0.0001 per share
- Symbol
- MRAI
- Exchange
- Not supplied
- Classification
- COMMON
Filing context
Context: AsOf2026-07-29
Dimensions: Not supplied
Accession 000121390026084129 · 1 registered-security cover member
Read the exact SEC filing ↗Disclosure sections
Items 1.01, 3.02, 5.03, 8.01, 9.01Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 1.01Item 1.01 - Entry into Material Agreement
Item 1.01 Entry into a Material Definitive
Agreement.
On July 29, 2026, Marpai,
Inc. (the “Company”) entered into securities purchase agreements (each, a “Securities Purchase Agreement”) with
accredited investors relating to an offering (the “Offering”) and the sale of an aggregate of 12,100 shares of newly designated
Series A Preferred Stock (the “Preferred Stock”) at a purchase price of $1,000 for each share of Preferred Stock. The aggregate
gross proceeds to the Company from the Offering are expected to be approximately $12,100,000. The initial closing of the Offering is expected
to occur on or about July 31, 2026 (the “Initial Closing”).
On July 31, 2026, the
Company filed the Certificate of Designation of Preferences Rights and Limitations of Series A Preferred Stock (the “Certificate
of Designation”) with the Secretary of State of the State of Delaware. Each share of Preferred Stock is convertible at the option
of the holder, subject to certain beneficial ownership limitation as set forth in the Certificate of Designation, into such number of
Common Stock, which shall be determined by dividing the stated value of $1,000 by the conversion price of $1.00, subject to certain adjustments
in the event of stock splits, stock dividends, and similar transactions. In addition, each share of Preferred Stock will automatically
convert into Common Stock upon a qualified public offering or a vote of sixty percent (60%) of the holders of Preferred Stock. The Preferred
Stock also provides that upon a liquidity event or a conversion to Common Stock, holders of the Preferred Stock will be entitled to receive
an eight percent (8%) dividend payable in Common Stock.
The Preferred Stock will
vote together with the Common Stock as a single class on all matters submitted to the vote of the stockholders of the Company on an as-converted
basis, except as otherwise required by law. Upon any liquidation, dissolution or winding-up of the Company, after the satisfaction in
full of the debts of the Company and payment of the liquidation preference to the Senior Securities (as defined in the Certificate of
Designation), holders of Preferred Stock shall be entitled to be paid, on a pari passu basis with the payment of any liquidation preference
afforded to holders of any Parity Securities (as defined in the Certificate of Designation) out of (but only to the extent) the assets
of the Company that are legally available for distribution to its stockholders, in the manner described in the Certificate of Designation.
In conjunction with the
execution of the Purchase Agreements, the Company and the Mitchell Family Trust II, who acted as the lead investor in the Offering, entered
into a board observer agreement (the “Board Observer Agreement”), pursuant to which Steve Mitchell will serve as an observer
to the board of directors of the Company. Pursuant to the Board Observer Agreement, Mr. Mitchell will be entitled to serve as a board
observer for a period of two (2) years, provided that the lead investor continues to own at least 3,000 shares of Preferred Stock.
Pursuant to the terms
of the Purchase Agreement, the Company agreed to file a registration statement within sixty (60) calendar days of the closing of the offering,
and use commercially reasonable efforts to cause such registration statement to become effective within ninety (90) days following closing
date. In addition, pursuant to the Purchase Agreement, the Company agreed to provide any purchaser who continues to own such number of
shares of Preferred Stock equal to ten percent (10%) of the Company’s issued and outstanding shares of Common Stock, such purchaser
shall be entitled to receive certain information rights. In addition, for a period of twenty-four (24) months, each purchaser who purchased
at least fifty (50) shares of Preferred Stock will be entitled to certain rights to participate in future equity offerings of the Company.
Subject to certain conditions, the Purchase Agreement also provides the purchasers of Preferred Stock with most-favored nation treatment,
giving them the right to amend their securities if the Company issues securities with more favorable terms while the investor’s
securities are outstanding, subject to certain exceptions and limitations. Such most-favored nation treatment expires upon the earlier
of the Company completing an underwritten public offering of common stock at a price per share equal to 100% of the initial Conversion
Price of the Preferred Stock for gross proceeds of at least $5 million, and the date or the occurrence of an event specified by the vote
or written consent of the holders then holding at least 60% of the then-outstanding shares of Preferred Stock.
The Purchase Agreements
contain representations and warranties that the parties made to the others in the context of all of the terms and conditions of that agreement
and in the context of the specific relationship between the parties. The provisions of such agreements, including the representations
and warranties contained therein, are not for the benefit of any party other than the parties to such agreements and are not intended
as documents for investors and the public to obtain factual information about the current state of affairs of the parties to that agreement.
Rather, investors and the public should look to other disclosures contained in the Company’s filings with the U.S. Securities and
Exchange Commission.
The securities to be
issued in the Offering are exempt from the registration requirements of the Securities Act pursuant to Section 4(a)(2) of the Securities
Act and/or Rule 506(b) of Regulation D promulgated thereunder. The securities have not been registered under the Securities Act and may
not be resold in the United States absent registration or an exemption from registration.
This Current Report on
Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities
in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under
the securities laws of any such state or jurisdiction.
The forgoing description
of the Certificate of Designation, the Purchase Agreement and the Board Observer Agreement are qualified by reference to the full text
of these documents, copies of which are filed as Exhibit 3.1, Exhibit 10.1, and Exhibit 10.2 respectively, to this Current Report on Form
8-K.
Item 3.02Item 3.02 - Unregistered Sales of Equity
Item 3.02
Unregistered Sales of Equity Securities.
The response to this
item is included in Item 1.01, Entry into a Material Definitive Agreement, and is incorporated herein in its entirety.
Item 5.03Item 5.03 - Amendments to Articles/Bylaws
Item 5.03
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
The Certificate of Incorporation of the Company
authorizes the issuance of up to 2,000,000 shares of preferred stock and further authorizes the Board of the Company to fix and determine
the designation, preferences, conversion rights, or other rights, including voting rights, qualifications, limitations, or restrictions
of the preferred stock.
On July 31, 2026, the Company filed the Certificate
of Designation, designating 12,100 shares of Preferred Stock in connection with the Offering.
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
On July 29, 2026, the Company issued a press release,
titled “Marpai. Announces $12 Million Private Placement led by Mitchell Companies.” A copy of the press release is attached
as Exhibit 99.1 hereto and is incorporated by reference herein.
Filed exhibits (1)
EX-99.1 (by filename) ea030013901ex99-1.htmEX-99.1
5
ea030013901ex99-1.htm
PRESS RELEASE, TITLED "MARPAI. ANNOUNCES $12 MILLION PRIVATE PLACEMENT LED BY MITCHELL COMPANIES."
Exhibit 99.1
Marpai Announces
$12 Million Private Placement led by Mitchell Companies
Tampa, Florida -
July 29, 2026 - Marpai, Inc. (“Marpai” or the “Company”) (OTCQX: MRAI), a leader in innovative healthcare
technology, Third-Party Administration (“TPA”), and Pharmacy Benefit Management (“PBM”) services, today announced
that it entered into securities purchase agreements with accredited investors in a private placement of newly designated convertible
preferred stock. The offering was led by Mitchell Companies.
The investment is intended
to accelerate Marpai’s growth trajectory, strengthen its technology-enabled healthcare services platform, advance the Company’s
mission of delivering smarter, more efficient healthcare administration solutions for employers, members, brokers, and healthcare partners,
and strengthen Marpai’s financial position.
Driving Innovation
in Healthcare Administration
Marpai is redefining
the TPA and PBM landscapes by empowering self-funded employers to maximize plan performance, drastically reduce healthcare spend, and
…
Open exhibit ↗